Evidence map›Paper›PMID 40731352›Full record

ArticleBMC health services research2025

Assessing direct medical costs of children following a new prescription of ADHD medication.

Milica Paut Kusturica, Alba Sánchez-Viñas, Blanca Lumbreras, Maria Elena Huerta-Ramos, Ignacio Aznar-Lou, Maria Rubio-Valera

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC health services research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Milica Paut Kusturica *Department of Pharmacology and Toxicology, Faculty of Medicine Novi Sad, University of Novi Sad, Novi Sad, Serbia.
Alba Sánchez-Viñas *Health Technology Assessment in Primary Care and Mental Health (PRISMA) Research Group, Institut de Recerca Sant Joan de Déu, Santa Rosa 39-57, Esplugues de Llobregat, 08950, Spain.
Blanca LumbrerasCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Maria Elena Huerta-RamosHealth Technology Assessment in Primary Care and Mental Health (PRISMA) Research Group, Institut de Recerca Sant Joan de Déu, Santa Rosa 39-57, Esplugues de Llobregat, 08950, Spain.
Ignacio Aznar-LouHealth Technology Assessment in Primary Care and Mental Health (PRISMA) Research Group, Institut de Recerca Sant Joan de Déu, Santa Rosa 39-57, Esplugues de Llobregat, 08950, Spain. ignacio.aznar@sjd.es.
Maria Rubio-ValeraHealth Technology Assessment in Primary Care and Mental Health (PRISMA) Research Group, Institut de Recerca Sant Joan de Déu, Santa Rosa 39-57, Esplugues de Llobregat, 08950, Spain.

Funding

Institute of Health Carlos III CP22/00029
6 · The paper itself

Abstract

purposeAttention-deficit/hyperactivity disorder (ADHD) is a prevalent childhood neurobehavioral disorder, imposing significant economic burdens on healthcare and society. This study aimed to examine healthcare resource utilisation and direct medical costs for paediatric ADHD patients in Catalonia, Spain, following their first ADHD treatment prescription.

methodsUsing real-world data from electronic healthcare records, this longitudinal register-based cohort study included all patients aged 6 to 18 years old who received a new centrally acting sympathomimetic treatment (ATC code N06BA) in the public healthcare system in Catalonia between 2016 and 2017. Healthcare resource utilisation and costs were analysed one year post-prescription, stratified by age (6-11, 12-14 and 15-18) and sex, for 3,507 patients.

resultsPrimary care (PC) physicians and nurses were the most utilised healthcare resources averaging about two and one visits per year, respectively. Costs peaked in the 11-14 age group, except for mental health hospitalisation costs, which were higher in other age groups; conversely, the adolescent group (15-18) had the lowest expenditure. ADHD patients showed high healthcare resource utilisation and costs within a year following the initial treatment prescription.

conclusionsFuture studies should explore the broader economic impact of ADHD, including costs within educational and social systems.

Indexed as

Attention Deficit Disorder with HyperactivityCentral Nervous System StimulantsHealth Care CostsAdolescentChildFemaleHumansLongitudinal StudiesMalePrimary Health CareSpainCentral Nervous System StimulantsAttention-deficit/hyperactivity disorderCost analysisDirect medical costsHealthcare utilisationPaediatricsReal-world data

Identifiers

PMID40731352
PMCPMC12309166

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.